$WSBC

WesBanco Declares Quarterly Cash Common and Preferred Stock Dividends

WesBanco, Inc. (Nasdaq: WSBC) announced quarterly cash dividends: $0.38 per common share (annualized $1.52) and $0.4609 per depositary share for Series B Preferred Stock. Both dividends are payable on October 1, 2026, to shareholders of record on September 4, 2026. The company has $27.8B in total assets as of June 30, 2026.

Original reporting
Published Aug 19, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
WesBanco Declares Quarterly Cash Common and Preferred Stock Dividends — source image
Decision brief

The 30-second read

$WSBCBullishHigh
01

Why it matters

The dividend announcements provide fresh income data that could influence investor allocation.

02

Market read

Income‑focused investors may consider WSBC and WSBCO for yield exposure.

03

What to watch

Potential impact of loan‑loss provisions on dividend sustainability.

Relevance 6/10Novelty 7/10Timing: announced Aug 19 2026

Background

WesBanco is a multi‑state bank holding company with $27.8 bn in assets.

Company-level read

Ticker impact

$WSBCBullishHigh confidence
Context

WesBanco announced a quarterly cash dividend of $0.38 per common share, payable Oct 1, 2026.

Expected impact

Potential modest upside as yield‑seeking buyers add positions.

Evidence & confidence

New dividend declaration is a primary corporate action with clear cash flow benefit.

$WSBCOBullishHigh confidence
Context

WesBanco declared a quarterly cash dividend on its 7.375% Series B preferred stock, $0.4609 per depositary share.

Expected impact

Likely stable or slightly higher price for the preferred shares.

Evidence & confidence

First report of the preferred dividend provides fresh yield information.

Market effects

May boost sentiment toward regional banks offering attractive yields.

Positive for Mid‑Atlantic banking sector.

Limited to U.S. regional banking investors.

Counterpoint

Yield may be insufficient if interest rates rise further.

Key entities

  • WesBanco, Inc.

    Regional bank announcing dividend.

Related articles

$WSBCMed

WesBanco Announces Second Quarter 2026 Financial Results

WesBanco, Inc. (Nasdaq: WSBC) reported Q2 2026 net income of $88.4 million and diluted EPS of $0.91, versus $54.9 million and $0.57 in Q2 2025. For six months ended June 30, 2026, net income was $172.8 million and diluted EPS $1.79. The bank cited 8.3% annualized loan growth, NIM of 3.63%, and an efficiency ratio of 51.2%.

$WSBCMed

WESBANCO INC (WSBC): Results of Operations and Financial Condition

WESBANCO INC (WSBC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 wsbc-ex99_1.htm EX-99.1 EX-99.1 WesBanco Announces Second Quarter 2026 Financial Results Marked by strong annualized loan growth, top-tier efficiency ratio, and accelerating growth in targeted expansion markets Wheeling, WVa. (July 21, 2026) – WesBanco, Inc. (“WesBanco”

$WSBCLow

WESBANCO INC (WSBC): Results of Operations and Financial Condition

WESBANCO INC (WSBC) filed an SEC Form 8-K — Results of Operations and Financial Condition. 8-K 0000203596 false 0000203596 us-gaap:SeriesBPreferredStockMember 2026-07-02 2026-07-02 0000203596 us-gaap:CommonStockMember 2026-07-02 2026-07-02 0000203596 2026-07-02 2026-07-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pu

$TTEMed

TotalEnergies (TTE) Eyes a Bigger $16 Billion Bet on Iraq: Could this Unlock More Growth?

TotalEnergies (TTE) and Iraq's government are discussing energy projects, potentially increasing investments from $12B to $16B. CEO Patrick Pouyanne aims to boost Iraq's oil production, leveraging existing infrastructure like the $10B Gas Growth Integrated Project (GGIP). Projects could support TTE's 3% production growth target by 2026, but details and geopolitical risks remain unclear.

$VKTXHighAI 8/10

What Viking Therapeutics Stock Means For Shareholders After Obesity Drug Data And $500 Million Raise

Viking Therapeutics (VKTX) reported positive obesity drug data for VK2735 and raised $500M, including $275M in common stock and $225M in convertible notes. The funds support R&D and Phase 3 trials but introduce future dilution risks. Analysts project $118.5M revenue and $12.9M earnings by 2029, with some forecasting higher figures. The company has no revenue and reported a $358.5M loss in 2025.